Zhuhai Yisheng Biopharmaceutical Co., Ltd., Bei Fushu, a well-known eye drop brand, a famous trademark in Guangdong Province, is a high-tech enterprise specializing in the research, development, production and sales of trauma repair biotechnology drugs using genetic engineering technology
Zhuhai Yisheng Biopharmaceutical Co., Ltd., founded in 1996, is the implementation unit of the National Torch Plan and the outstanding enterprise of Guangdong Province in 2013. In 2011, it was rated as a high-tech enterprise, and in 2012, it became the implementation unit of major projects of strategic emerging industries in Zhuhai. In 2001, Esheng Biotech Group was listed on the Growth Enterprise Market of Hong Kong, and in 2011, it was successfully transferred to the main board of the company under the stock code 1061. In 2010, the company established a new factory in Zhuhai High-tech Zone in accordance with the new GMP standard, covering an area of more than 13,000 square meters, with a building area of 20,000 square meters, introducing world-class advanced equipment and production lines, and in 2013, successfully passed the national new GMP certification, laying a solid foundation for the company's expansion and development.
The company is committed to the use of genetic engineering technology to develop, produce and sell trauma repair biotechnology drugs with independent intellectual property rights, including ocular surface repair, body surface trauma repair and nerve injury repair treatment drugs. In the research and development and manufacturing of recombinant bovine basic fibroblast growth factor (rb-bFGF), it has reached the world's advanced and domestic leading level. In 2012, the R&D and industrialization of rb-bFGF was included in the major projects of strategic emerging industries in Zhuhai. In addition, the company has established the world's leading "blow-fill-seal" aseptic production technology platform, which has enabled the company's ophthalmic drug production technology to reach the international advanced level and greatly improved the company's core competitiveness in the field of ophthalmology. The company actively participates in a number of major national scientific and technological research projects, participates in the research and formulation of quality control standards and standard products for biotechnology drugs in China, and has won the second prize of the National Science and Technology Progress Award.
At present, the company has successfully developed and put into commercial production biological drugs, including three national Class I new drugs and two national Class IV new drugs. The main products are: Bei Fu Ji external solution, Bei Fu Ji freeze-dried preparation, Bei Fu Xin gel, Bei Fu Shu eye drops and Bei Fu Shu eye gel. Bei Fuji and Bei Fushu are used for the treatment of body surface trauma and ocular surface injury repair respectively, and are the first new drugs to be marketed at home and abroad, and have been rated as national new products. At present, Beifushu has become the first-line drug and the preferred brand for the clinical treatment of corneal injury repair.
In 2014, Zhuhai Esheng Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, entered into an import and service agreement with Pfizer International Trading (Shanghai) Co., Ltd. ("Pfizer"), whereby Pfizer authorized Esia Pharma as its exclusive import distributor and exclusive market developer of Sulida ® eye drops and Xerica ® eye drops (collectively, "Pfizer Ophthalmic Products") in Chinese mainland. Pfizer's ophthalmic products are all intraocular blood pressure lowering drugs. The establishment of a business partnership with Pfizer will enable us to share distribution channels with Pfizer, while enhancing our brand image and product portfolio in the field of ophthalmology in China.
The company actively cooperates with domestic and foreign scientific research institutions to track the latest development of biotechnology, and continuously research, develop and promote innovative biotherapeutic products to improve human health and improve the quality of life.
